Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost bought 1,800 shares of the firm’s stock in a transaction on Friday, October 14th. The shares were acquired at an average price of $9.48 per share, for a total transaction of $17,064.00. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $29,093,655.48. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, October 13th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The shares were purchased at an average cost of $9.52 per share, with a total value of $51,408.00.
  • On Tuesday, October 11th, Phillip Md Et Al Frost purchased 7,200 shares of Opko Health stock. The shares were purchased at an average cost of $9.78 per share, with a total value of $70,416.00.
  • On Monday, October 10th, Phillip Md Et Al Frost purchased 24,800 shares of Opko Health stock. The shares were purchased at an average cost of $9.82 per share, with a total value of $243,536.00.
  • On Thursday, October 6th, Phillip Md Et Al Frost purchased 4,200 shares of Opko Health stock. The shares were purchased at an average cost of $10.53 per share, with a total value of $44,226.00.
  • On Tuesday, October 4th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The shares were purchased at an average cost of $10.57 per share, with a total value of $38,052.00.
  • On Friday, September 30th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $10.54 per share, with a total value of $18,972.00.
  • On Thursday, September 29th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The shares were purchased at an average cost of $10.67 per share, with a total value of $38,412.00.
  • On Wednesday, September 28th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The shares were purchased at an average cost of $11.01 per share, with a total value of $59,454.00.
  • On Tuesday, September 27th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $11.16 per share, with a total value of $20,088.00.
  • On Monday, September 26th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $11.04 per share, with a total value of $19,872.00.

Opko Health Inc. (NYSE:OPK) traded down 1.48% during midday trading on Monday, hitting $9.31. 3,352,742 shares of the stock traded hands. The company has a market capitalization of $5.12 billion and a price-to-earnings ratio of 38.95. Opko Health Inc. has a 52 week low of $7.12 and a 52 week high of $11.85. The stock’s 50-day moving average price is $10.08 and its 200 day moving average price is $10.07.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $357.10 million for the quarter, compared to analysts’ expectations of $324.11 million. Opko Health’s revenue was up 742.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.09) EPS. On average, equities research analysts predict that Opko Health Inc. will post ($0.05) EPS for the current year.

Insider Buying and Selling by Quarter for Opko Health (NYSE:OPK)

OPK has been the subject of several research reports. Jefferies Group reissued a “hold” rating on shares of Opko Health in a research note on Wednesday, August 17th. JPMorgan Chase & Co. set a $14.00 price objective on shares of Opko Health and gave the company a “buy” rating in a research note on Tuesday, August 9th. Oppenheimer Holdings Inc. reissued an “outperform” rating on shares of Opko Health in a research note on Saturday, June 25th. Standpoint Research increased their price objective on shares of Opko Health from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, June 21st. Finally, Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $13.20.

A number of institutional investors have recently modified their holdings of OPK. Janus Capital Management LLC boosted its position in shares of Opko Health by 0.6% in the second quarter. Janus Capital Management LLC now owns 15,800 shares of the company’s stock valued at $148,000 after buying an additional 100 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its position in shares of Opko Health by 1.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 22,945 shares of the company’s stock valued at $214,000 after buying an additional 261 shares in the last quarter. Gilman Hill Asset Management LLC boosted its position in shares of Opko Health by 0.6% in the second quarter. Gilman Hill Asset Management LLC now owns 46,661 shares of the company’s stock valued at $436,000 after buying an additional 298 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Opko Health by 1.1% in the third quarter. Fisher Asset Management LLC now owns 38,229 shares of the company’s stock valued at $405,000 after buying an additional 403 shares in the last quarter. Finally, Capstone Asset Management Co. boosted its position in shares of Opko Health by 3.3% in the third quarter. Capstone Asset Management Co. now owns 16,216 shares of the company’s stock valued at $172,000 after buying an additional 520 shares in the last quarter.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.